“…The current policies of TKI treatment of chronic phase CML mandate using TKIs at their respective approved or maximum tolerated doses lifelong, with the possibility of opening a window for treatment discontinuation when a DMR has been achieved and maintained for an as yet unspecified period of time. 3 , 5 , 12 , 16 , 40 The window for treatment discontinuation can be enlarged in some of the patients who received imatinib first line, by switching early or late to a second-generation TKI, 40 , 41 , 42 , 43 as well as using second-generation TKIs first line. 17 , 18 , 19 , 20 , 44 , 45 Other policies have not been tested prospectively, particularly for treatments alternative to discontinuation, when discontinuation is not possible.…”